Hospira Launches Generic Oxaliplatin Injection

Friday, September 18, 2009 General News
Email Print This Page Comment
Font : A-A+



LAKE FOREST, Ill., Aug. 11 Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval and launch of oxaliplatin injection in the United States. The medication is a generic version of Sanofi-Aventis' Eloxatin(R), which posted 2008 U.S. sales of approximately $1.4 billion. Hospira's oxaliplatin injection is one of the first generic versions of this drug to come in solution form. The innovator drug is also in solution form. Oxaliplatin injection, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor, and in the treatment of advanced colorectal cancer.

"Hospira's launch of oxaliplatin injection in solution form gives our customers a generic alternative of this critical medication in the formulation they seek," said Sue Hazelwood, vice president and general manager, alternate site, U.S., Hospira. "This is another example of Hospira's dedication to providing high-quality products that will reduce costs in the oncology space."

Hospira will initially offer oxaliplatin injection in 50 mg and 100 mg single-use vials.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated formats, several of which are proprietary, such as its ADD-Vantage(R) drug delivery system and iSecure(R) prefilled syringes. Therapeutic areas include anesthesia, anti-infectives, analgesics, cardiovascular, oncology, emergency and other areas. Hospira has approximately 25 generic drugs scheduled to launch in various regions around the world in 2009 and 2010.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including projections of certain measures of Hospira's results of operations, projections of certain charges and expenses, and other statements regarding Hospira's goals and strategy. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which is incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.

Private Securities Litigation Reform Act of 1995 -- A Caution Concerning Forward-Looking Statements

SOURCE Hospira, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook